| CAS NO: | 21498-08-8 |
| 包装 | 价格(元) |
| 10mM (in 1mL Water) | 电议 |
| 50mg | 电议 |
| Cas No. | 21498-08-8 |
| 别名 | 盐酸洛非西定; Baq-168; MDL-14042 |
| 化学名 | 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole, monohydrochloride |
| Canonical SMILES | ClC1=CC=CC(Cl)=C1OC(C)C2=NCCN2.Cl |
| 分子式 | C11H12Cl2N2O o HCl |
| 分子量 | 295.6 |
| 溶解度 | ≥ 11.15mg/mL in Water |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Lofexidine is a α2-Receptor agonist for opioid detoxification. Lofexidine shows a strong affinity for the α2A-receptor subtype [1]. The α2 adrenergic receptor is a G protein-coupled receptor (GPCR) consisting three highly homologous subtypes, α2A-, α2B-, and α2C-adrenergic. The α-receptors in brain are important presynaptic modulators of central noradrenergic function (autoreceptors) and postsynaptic mediators of many effects of catecholamines and related drugs. The α2-adrenergic agonists can be used as antihypertensives and preanesthetic agents [2]. Lofexidine is extensively absorbed, reaching peak concentrations at approximately 3 hours after oral administration. The mean maximum serum concentrations following a single 1.2 or 2.0 mg dose in healthy male adults were 1755 ± 306 and 2795 ± 593 ng/ml, respectively [1]. Clinical trials: Lofexidine has entered clinical trials in the patients treatment of opiate withdrawal. Lofexidine-treated patients experienced a rebound increase in blood pressure following discontinuation of lofexidine. The most frequently reported adverse events were insomnia, dry mucous membranes, sedation, dizziness, and asthenia [1]. References: |
m.cnreagent.com